Title:
COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES
Document Type and Number:
WIPO Patent Application WO1996005838
Kind Code:
A3
Abstract:
A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases.
Inventors:
SCHOENHARTING MARTIN (DE)
MUELLNER STEFAN (DE)
ZABEL PETER (DE)
MUELLNER STEFAN (DE)
ZABEL PETER (DE)
Application Number:
PCT/EP1995/003125
Publication Date:
April 11, 1996
Filing Date:
August 07, 1995
Export Citation:
Assignee:
HOECHST AG (DE)
SCHOENHARTING MARTIN (DE)
MUELLNER STEFAN (DE)
ZABEL PETER (DE)
SCHOENHARTING MARTIN (DE)
MUELLNER STEFAN (DE)
ZABEL PETER (DE)
International Classes:
A61K31/195; A61K31/44; A61K31/52; A61K31/55; A61K38/00; A61K31/70; A61K38/13; A61K45/06; A61P1/16; A61P3/06; A61P3/08; A61P11/00; A61P17/00; A61P27/16; A61P29/00; A61P37/06; A61P37/08; (IPC1-7): A61K31/55; A61K31/52; A61K38/13; A61K45/06
Foreign References:
| EP0234262A1 | 1987-09-02 | |||
| EP0544391A1 | 1993-06-02 | |||
| EP0490181A1 | 1992-06-17 | |||
| EP0493682A2 | 1992-07-08 |
Other References:
REECE D E ET AL: "CHRONIC GRAFT VERSUS-HOST DISEASE CGVHD IN PATIENTS PTS RECEIVING UNRELATED DONOR UD ALLOGENEIC BONE MARROW TRANSPLANTS ALLO BMTS INCIDENCE RISK FACTORS AND OUTCOME", ANNUAL MEETING OF THE CANADIAN SOCIETY FOR CLINICAL INVESTIGATION AND THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA, OTTAWA, ONTARIO, CANADA, SEPTEMBER 11-14, 1992. CLIN INVEST MED, 15 (4 SUPPL.). 1992. A61.
D.J. STEWART ET AL.: "Addition of Pentoxifylline plus Nifedipine to chemotherapy in patients with Cisplatin-resistant cancers of the lung and other sites.", AM J CLIN ONCOL, vol. 17, no. 4, pages 313 - 316
G. BERKENBOOM ET AL.: "Prevention of Cyclosporine A-induced vascular toxicity by Pentoxifylline", J CARDIOVASC PHARMACOL, vol. 18, no. 5, pages 761- - 768
B. SARRIA ET AL.: "The Nicardipine-Isoprenaline interaction in human and guinea-pig isolated airways", FUNDAM CLIN PHARMACOL, vol. 8, no. 1, 16 February 1994 (1994-02-16), pages 26 - 33
K.S. GALDAL ET AL.: "Inhibition of the thromboplastin response of endothelial cells in vitro", BIOCHEM PHARMACOL, vol. 33, no. 17, pages 2723 - 2726
CARRIER M ET AL: "Effect of pentoxifylline on renal toxicity of cyclosporine: preliminary results.", TRANSPLANT PROC, OCT 1994, 26 (5) P2745-6, UNITED STATES
KHABAR K S A ET AL: "Pentoxifylline selectively potentiates cyclosporin A (CYA)-mediated suppression of mixed lymphocyte cytotoxicity (MLC) among other immunological functions", THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29, 1995; CONFERENCE PAPER, pages 852
D.J. STEWART ET AL.: "Addition of Pentoxifylline plus Nifedipine to chemotherapy in patients with Cisplatin-resistant cancers of the lung and other sites.", AM J CLIN ONCOL, vol. 17, no. 4, pages 313 - 316
G. BERKENBOOM ET AL.: "Prevention of Cyclosporine A-induced vascular toxicity by Pentoxifylline", J CARDIOVASC PHARMACOL, vol. 18, no. 5, pages 761- - 768
B. SARRIA ET AL.: "The Nicardipine-Isoprenaline interaction in human and guinea-pig isolated airways", FUNDAM CLIN PHARMACOL, vol. 8, no. 1, 16 February 1994 (1994-02-16), pages 26 - 33
K.S. GALDAL ET AL.: "Inhibition of the thromboplastin response of endothelial cells in vitro", BIOCHEM PHARMACOL, vol. 33, no. 17, pages 2723 - 2726
CARRIER M ET AL: "Effect of pentoxifylline on renal toxicity of cyclosporine: preliminary results.", TRANSPLANT PROC, OCT 1994, 26 (5) P2745-6, UNITED STATES
KHABAR K S A ET AL: "Pentoxifylline selectively potentiates cyclosporin A (CYA)-mediated suppression of mixed lymphocyte cytotoxicity (MLC) among other immunological functions", THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29, 1995; CONFERENCE PAPER, pages 852
Download PDF:
Previous Patent: USE OF N-SUBSTITUTED PHENOTHIAZINES
Next Patent: 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES
Next Patent: 2,3-DIHYDRO-1-(2,2,2-TRIFLUOROETHYL)-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPINES